Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Oppenheimer Maintains Outperform Rating for Etsy, Lowers Price Target To $175

Oppenheimer has decided to maintain its Outperform rating of Etsy (NASDAQ:ETSY) and lower its price target from $215.00 to $175.00. Shares of Etsy are trading up 4.36% over the last 24 hours, at $117.87 per share. A move to $175.00 would account for a 48.47% increase from the current share…

Benzinga

Stifel Downgrades Rating to Hold for Reynolds Consumer, Lowers Price Target To $31

Stifel downgraded its rating of Reynolds Consumer (NASDAQ:REYN) to Hold with a price target of $31.00, changing its price target from $33.00 to $31.00. Shares of Reynolds Consumer are trading down 3.6% over the last 24 hours, at $28.38 per share.

Benzinga

Deutsche Bank Maintains Buy Rating for KLA, Lowers Price Target To $425

Deutsche Bank has decided to maintain its Buy rating of KLA (NASDAQ:KLAC) and lower its price target from $475.00 to $425.00. Shares of KLA are trading up 1.74% over the last 24 hours, at $336.00 per share. A move to $425.00 would account for a 26.49% increase from the current share…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Piper Sandler Maintains Overweight Rating for Patterson-UTI Energy, Raises Price Target To $20

Piper Sandler has decided to maintain its Overweight rating of Patterson-UTI Energy (NASDAQ:PTEN) and raise its price target from $14.50 to $20.00. Shares of Patterson-UTI Energy are trading up 3.93% over the last 24 hours, at $17.30 per share.

Benzinga

HC Wainwright & Co. Maintains Buy Rating for Ikena Oncology, Raises Price Target To $26

HC Wainwright & Co. has decided to maintain its Buy rating of Ikena Oncology (NASDAQ:IKNA) and raise its price target from $25.00 to $26.00. Shares of Ikena Oncology are trading up 7.06% over the last 24 hours, at $7.28 per share.

Benzinga

B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33

B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics are trading down 5.7% over the last 24 hours, at $23.48 per share.

Benzinga

Is Ideanomics a Smart Electric Vehicle Stock to Add to Your Portfolio?

Although electric vehicle company Ideanomics (IDEX) has been making several positive moves, it is on the brink of losing its Nasdaq listing. So, let’s evaluate if it is wise to bet on the stock now. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Walter And Jesse Are Back: Could A 'Breaking Bad' Reunion Boost AMC Ratings?

The wild tale of a high school chemistry teacher that becomes a meth manufacturer captured audiences and led to strong ratings for AMC Networks Inc (NASDAQ: AMCX).

Benzinga

Expert Ratings for Qorvo

Analysts have provided the following ratings for Qorvo (NASDAQ:QRVO) within the last quarter:

Benzinga

Where Caesars Entertainment Stands With Analysts

Analysts have provided the following ratings for Caesars Entertainment (NASDAQ:CZR) within the last quarter:

Benzinga

Where Bicycle Therapeutics Stands With Analysts

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:

Benzinga

AstroNova Q4 2022 Earnings Conference Call On April 14, 2022 At 09:00 AM ET

AstroNova (NASDAQ:ALOT) will host a conference call at 09:00 AM ET on April 14, 2022, to discuss Q4 2022 earnings results. How to Attend AstroNova (ALOT) Conference Call Follow this link to access the live webcast.

Benzinga

Here's Why Airbnb Shares Are Moving

Shares of several companies in the hotels, restaurants and leisure sectors, including Airbnb Inc (NASDAQ: ABNB), are trading higher amid overall market strength as stocks rebound following Tuesday weakness.

Benzinga

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21. Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's Why Camber Energy Shares Are Rising

Shares of oil, energy and oil services companies, including Camber Energy Inc (NASDAQ: CEI), are trading higher as oil prices gain. While the International Energy Agency reported a larger-than-expected build in US crude inventories, supply constraints continue to drive prices higher.

Benzinga

More Analysts Re-Rate Netflix Ahead Of Q1 Earnings

Analysts re-rated Netflix Inc (NASDAQ: NFLX) ahead of its Q1 results.

Benzinga

Where KLA Stands With Analysts

Within the last quarter, KLA (NASDAQ:KLAC) has observed the following analyst ratings:

Benzinga

Expert Ratings for Intuitive Surgical

Within the last quarter, Intuitive Surgical (NASDAQ:ISRG) has observed the following analyst ratings:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Cisco Systems Whale Trades For April 13

Someone with a lot of money to spend has taken a bearish stance on Cisco Systems (NASDAQ:CSCO). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Advanced Micro Devices

Someone with a lot of money to spend has taken a bullish stance on Advanced Micro Devices (NASDAQ:AMD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Expert Ratings for Okta

Okta (NASDAQ:OKTA) has observed the following analyst ratings within the last quarter:

Benzinga

What 4 Analyst Ratings Have To Say About Quanterix

Over the past 3 months, 4 analysts have published their opinion on Quanterix (NASDAQ:QTRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Where Blueprint Medicines Stands With Analysts

Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Pete Najarian Buys Upside Call Options In Apple, Chevron And This Stock Up More Than 60% YTD

Current market conditions are ripe for active traders, according to Market Rebellion co-founder Pete Najarian. That's why he bought call options in a handful of names this week.

Benzinga

Why This Legendary Tesla Investor Plans To Hold EV Stock For At Least 8 More Years

One of the most long-terms bulls of electric vehicle leader Tesla Inc (NASDAQ: TSLA) recently doubled down on his projection for how much the company could be worth in the next eight to 10 years.

1 … 697 698 699 700

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.